banner

Call for Late Breaking
Clinical Trial AbstractS

Important Information

The Late Breaking Clinical Trials submission site is open now. Each abstract submission will require a fee of SGD 50. This fee will fund the publishing of the APHRS2022 abstracts on the Journal of Arrhythmia.

Payments must be made by credit card during the submission process. Visa and MasterCard are accepted.

Closing Date: 30 September 2022
Notification on Acceptance/Rejection: 14 October 2022

Abstract Author Designation

The Submitting Author is considered the Presenting Author. All correspondence for the abstract will be directed to the Submitting/Presenting Author. Once the abstract has been submitted, the Presenting Author cannot be changed.


Criteria

Evaluation will be based on the following criteria:

1. Impact of the research
2. Novelty and rigor of the study design
3. Clinical endpoints
4. Quality of the statistical plan


Rules for Submission Eligibility

  • If an abstract submission has already been accepted for APHRS2022, it will not be eligible for a Late Breaking Clinical Trials submission.
  • Submissions are not eligible for consideration if the manuscript of the submission will be published prior to APHRS2022.
  • Submissions are not eligible for consideration if the trial results have been presented at a major international meeting held prior to APHRS2022).
  • Submissions which appear to be redundant versions of a single study and/or selling a product versus discussing the science will be rejected.



Late Breaking Clinical Trials Categories

1. Late-Breaking Randomized Clinical Trials: First-time presentation of primary or major secondary results from a prospective, randomized clinical trial.

2. Late-Breaking Clinical Innovations: First-time presentation of results of clinical applications of novel therapeutic or diagnostic approaches to heart rhythm disorders.

3. Late-Breaking Clinical Trials Updates and Registries: Follow-up analyses from prospective, randomized clinical trials or first-time presentation of high-impact information from multicenter clinical registries or observational studies.

4. Late-Breaking Science: Innovative research that includes the latest breakthroughs in basic and/or clinical science that could have a significant impact on clinical practice.


Abstract Title

  • An abstract must have a short specific title (containing no abbreviations) that indicates the nature of the investigation.
  • Titles should not include the authors’ names.
  • Always use correct title case (e.g., Only the Best of the Best in Medicine Study Electrophysiology).


Abstract Author

  • The Submitting Author is the Presenting Author. All correspondence for the abstract will be directed to the Submitting Author, and therefore, their information should be reviewed to ensure that current and correct email address information is listed. This designation should be carefully considered before initiating the abstract submission process.
  • Once the abstract has been submitted, the Submitting /Presenting Author cannot be changed.
  • Only one investigator per trial may be considered the Presenting Author.
  • The Submitting Author must guarantee that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors.
  • If an investigator belongs to multiple submissions, the investigator’s name must be identical in each submission.
  • A completed submission constitutes a commitment by an investigator to present if accepted.


Abstract Text

When entering text, please remember:

  • Use generic drug names.
  • Do not begin sentences with numerals.
  • Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
  • Do not include references, credits, or grant support.
  • Do not include the names or personal information of any patient participating in the study or trial.


Abstract Structure

1. The abstract must be written in English.

2. Novelty and rigor of the study design

3. Author(s)' name(s) and Affiliation (s); a maximum of 10 co-authors can be listed to the abstract

4. Abstract may be submitted in one of the following formats:

Text-only Abstracts - If your abstract does not contain picture, tables or graphs, complete your abstract submission in the CONTENT BOX. The maximum word count allowed for text-only abstracts is 2500 words.

Abstract with pictures, tables or graphs - If your abstract contains picture, tables or graphs, you must upload the full abstract including picture, tables or graphs as a SUPPORTING DOCUMENT.  You need to indicate "Abstract submitted under supporting document" in the CONTENT BOX. The maximum word count allowed for abstracts with pictures, tables or graphs is 2000 words.

SUPPORTING DOCUMENT should be prepared in PDF/DOCX file, and should not exceed 1.5 MB in file size.

5. The Abstract Body text is to be provided as follows:

  • Introduction
  • Methods
  • Application
  • Next Steps / Future

Note: Abstracts that do not follow the structure will be disregarded 


Abstract Data

  • Multiple abstracts appearing to be redundant versions of a single study will be rejected.
  • Abstracts are not eligible for consideration if published prior to APHRS2022. No abstract may be presented at APHRS2022 if it is substantially similar to material presented or to be presented at a major international meeting held prior to APHRS2022.
  • Individuals who have submitted abstracts to other major international meetings and await notification of acceptance may also submit abstracts for consideration a APHRS2022; however, upon acceptance from another organization, it is the responsibility of the author to notify the APHRS2022 Congress Secretariat to withdraw the abstract.
  • Industry Abstract Submissions: All submissions are required to focus on science and research and not products or services. Abstract presentation may not be sales presentations and/or endorsement for products or services.
  • The APHRS2022 reserves the rights of reproduction, distribution, display and derivatives in both print and digital format.


Abstract Revisions

  • Carefully proofread the abstract content and make any necessary revisions before the submission deadline date.
  • To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. This determines which team grades the abstract. If you select the appropriate category, you are more likely to be graded by peers with similar interests.
  • Resubmission of an abstract that is corrected or changed is not possible after the submission deadline date.


Accepted Submissions

  • Acceptance/Rejection Notification: Disposition announcements will be sent via email by 14 October 2022 to the investigator submitting the late breaking trial.
  • Accepted Late-Breaking Clinical Trial abstracts are embargoed until the time of presentation. This means that the Congress will release these abstracts the day of the presentation.
  • The APHRS2022 reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Co-authors reserve all proprietary rights other than copyright, such as patent rights and the right to use all or part of the application in future works of their own.
  • Titles and presenters will be listed online and printed APHRS2022 Program/Itinerary Planner. A copy of the abstracts will be uploaded on the online platform at the beginning of the Late-Breaking Clinical Trials Session.


Registration

The presenter of the trial will be required to register for APHRS2022 and will be charged a reduced registration rate. Only one author per abstract is considered the presenter. Co-Author(s) listed on the abstract do not receive reduced rates towards registration.


Presentation

  • All presenters must display a slide at the beginning of their presentation indicating disclosure information that may be applicable. Detailed information about slides and disclosing relationships will be provided to all presenters.
  • All presentations and discussions must be conducted in English.


banner

Read our Privacy Policy